240 related articles for article (PubMed ID: 18945463)
21. Interleukin-1- and type I interferon-dependent enhanced immunogenicity of an NYVAC-HIV-1 Env-Gag-Pol-Nef vaccine vector with dual deletions of type I and type II interferon-binding proteins.
Delaloye J; Filali-Mouhim A; Cameron MJ; Haddad EK; Harari A; Goulet JP; Gomez CE; Perdiguero B; Esteban M; Pantaleo G; Roger T; Sékaly RP; Calandra T
J Virol; 2015 Apr; 89(7):3819-32. PubMed ID: 25609807
[TBL] [Abstract][Full Text] [Related]
22. Experimental Leishmania major infection suppresses HIV-1 DNA vaccine induced cellular immune response.
Robinson TM; Nelson R; Artis D; Scott P; Boyer JD
Cells Tissues Organs; 2004; 177(3):185-8. PubMed ID: 15388992
[TBL] [Abstract][Full Text] [Related]
23. Vaccination of mice with replication-defective human immunodeficiency virus induces cellular and humoral immunity and protects against vaccinia virus-gag challenge.
Baliga CS; van Maanen M; Chastain M; Sutton RE
Mol Ther; 2006 Sep; 14(3):432-41. PubMed ID: 16713742
[TBL] [Abstract][Full Text] [Related]
24. [Intranasal priming with HIV DNA vaccine and systemic boosting with recombinant vaccinia induce vigorous immune responses: experiment with mice].
Huang XG; Xu JQ; Ren L; Qiu C; Zhang N; Liu LX; Wan YM; Peng H; Shao YM
Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(44):3109-13. PubMed ID: 17313761
[TBL] [Abstract][Full Text] [Related]
25. Attenuated rabies virus activates, while pathogenic rabies virus evades, the host innate immune responses in the central nervous system.
Wang ZW; Sarmento L; Wang Y; Li XQ; Dhingra V; Tseggai T; Jiang B; Fu ZF
J Virol; 2005 Oct; 79(19):12554-65. PubMed ID: 16160183
[TBL] [Abstract][Full Text] [Related]
26. Expression of interleukin-6 by a recombinant rabies virus enhances its immunogenicity as a potential vaccine.
Luo J; Zhang B; Wu Y; Tian Q; Zhao J; Lyu Z; Zhang Q; Mei M; Luo Y; Guo X
Vaccine; 2017 Feb; 35(6):938-944. PubMed ID: 28089546
[TBL] [Abstract][Full Text] [Related]
27. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.
Gómez CE; Nájera JL; Jiménez V; Bieler K; Wild J; Kostic L; Heidari S; Chen M; Frachette MJ; Pantaleo G; Wolf H; Liljeström P; Wagner R; Esteban M
Vaccine; 2007 Mar; 25(11):1969-92. PubMed ID: 17224219
[TBL] [Abstract][Full Text] [Related]
28. Role of novel type I interferon epsilon in viral infection and mucosal immunity.
Xi Y; Day SL; Jackson RJ; Ranasinghe C
Mucosal Immunol; 2012 Nov; 5(6):610-22. PubMed ID: 22617838
[TBL] [Abstract][Full Text] [Related]
29. Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model.
Otero M; Calarota SA; Felber B; Laddy D; Pavlakis G; Boyer JD; Weiner DB
Vaccine; 2004 Apr; 22(13-14):1782-90. PubMed ID: 15068862
[TBL] [Abstract][Full Text] [Related]
30. Type I Interferon Promotes Humoral Immunity in Viral Vector Vaccination.
Zhong C; Liu F; Hajnik RJ; Yao L; Chen K; Wang M; Liang Y; Sun J; Soong L; Hou W; Hu H
J Virol; 2021 Oct; 95(22):e0092521. PubMed ID: 34495698
[TBL] [Abstract][Full Text] [Related]
31. Enhancement of humoral and cellular immune responses by monophosphoryl lipid A (MPLA) as an adjuvant to the rabies vaccine in BALB/c mice.
Hu X; Liu R; Zhu N
Immunobiology; 2013 Dec; 218(12):1524-8. PubMed ID: 23816301
[TBL] [Abstract][Full Text] [Related]
32. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.
Shiver JW; Fu TM; Chen L; Casimiro DR; Davies ME; Evans RK; Zhang ZQ; Simon AJ; Trigona WL; Dubey SA; Huang L; Harris VA; Long RS; Liang X; Handt L; Schleif WA; Zhu L; Freed DC; Persaud NV; Guan L; Punt KS; Tang A; Chen M; Wilson KA; Collins KB; Heidecker GJ; Fernandez VR; Perry HC; Joyce JG; Grimm KM; Cook JC; Keller PM; Kresock DS; Mach H; Troutman RD; Isopi LA; Williams DM; Xu Z; Bohannon KE; Volkin DB; Montefiori DC; Miura A; Krivulka GR; Lifton MA; Kuroda MJ; Schmitz JE; Letvin NL; Caulfield MJ; Bett AJ; Youil R; Kaslow DC; Emini EA
Nature; 2002 Jan; 415(6869):331-5. PubMed ID: 11797011
[TBL] [Abstract][Full Text] [Related]
33. Ginsenoside Re as an adjuvant to enhance the immune response to the inactivated rabies virus vaccine in mice.
Su X; Pei Z; Hu S
Int Immunopharmacol; 2014 Jun; 20(2):283-9. PubMed ID: 24680943
[TBL] [Abstract][Full Text] [Related]
34. A role for granulocyte-macrophage colony-stimulating factor in the regulation of CD8(+) T cell responses to rabies virus.
Wanjalla CN; Goldstein EF; Wirblich C; Schnell MJ
Virology; 2012 May; 426(2):120-33. PubMed ID: 22341782
[TBL] [Abstract][Full Text] [Related]
35. Rabies virus-based vectors expressing human immunodeficiency virus type 1 (HIV-1) envelope protein induce a strong, cross-reactive cytotoxic T-lymphocyte response against envelope proteins from different HIV-1 isolates.
McGettigan JP; Foley HD; Belyakov IM; Berzofsky JA; Pomerantz RJ; Schnell MJ
J Virol; 2001 May; 75(9):4430-4. PubMed ID: 11287595
[TBL] [Abstract][Full Text] [Related]
36. Vaccination with a Shigella DNA vaccine vector induces antigen-specific CD8(+) T cells and antiviral protective immunity.
Shata MT; Hone DM
J Virol; 2001 Oct; 75(20):9665-70. PubMed ID: 11559798
[TBL] [Abstract][Full Text] [Related]
37. Intrinsic adjuvanting of a novel single-cycle flavivirus vaccine in the absence of type I interferon receptor signaling.
Winkelmann ER; Widman DG; Xia J; Ishikawa T; Miller-Kittrell M; Nelson MH; Bourne N; Scholle F; Mason PW; Milligan GN
Vaccine; 2012 Feb; 30(8):1465-75. PubMed ID: 22226862
[TBL] [Abstract][Full Text] [Related]
38. Pseudovirion particle production by live poxvirus human immunodeficiency virus vaccine vector enhances humoral and cellular immune responses.
Chen X; Rock MT; Hammonds J; Tartaglia J; Shintani A; Currier J; Slike B; Crowe JE; Marovich M; Spearman P
J Virol; 2005 May; 79(9):5537-47. PubMed ID: 15827168
[TBL] [Abstract][Full Text] [Related]
39. Enhanced humoral HIV-1-specific immune responses generated from recombinant rhabdoviral-based vaccine vectors co-expressing HIV-1 proteins and IL-2.
McGettigan JP; Koser ML; McKenna PM; Smith ME; Marvin JM; Eisenlohr LC; Dietzschold B; Schnell MJ
Virology; 2006 Jan; 344(2):363-77. PubMed ID: 16226782
[TBL] [Abstract][Full Text] [Related]
40. Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide.
Huang Y; Chen A; Li X; Chen Z; Zhang W; Song Y; Gurner D; Gardiner D; Basu S; Ho DD; Tsuji M
Vaccine; 2008 Mar; 26(15):1807-16. PubMed ID: 18329757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
